Real-time enrollment status for this monoclonal gammopathy of undetermined significance (mgus) clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 6:50 AM UTC
| NCT Number | NCT02269592 |
| Recruiting Status | Recruiting |
| Condition | Monoclonal Gammopathy of Undetermined Significance (MGUS) |
| Phase | Clinical Trial |
| Target Enrollment | 10,000 participants |
| Active Locations | 7 sites in the US |
| Sponsor | Dana-Farber Cancer Institute |
| Last Updated on CT.gov | May 7, 2026 (May 7, 2026) |
As of July 13, 2026: Clinical trial NCT02269592 is currently recruiting participants. This clinical trial study for monoclonal gammopathy of undetermined significance (mgus) is actively seeking new participants at 7 locations across the United States. The study is sponsored by Dana-Farber Cancer Institute. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT02269592 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 7 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT02269592 was last updated May 7, 2026 (May 7, 2026). HelloStudys verifies this status automatically.